Answers are grounded in this paper and cite their sources.
Abstract The Personalized Response-directed surgery and Adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma (PRADO trial) is an international, multicenter, single arm, non-randomized prospective phase 2 trial that investigated neoadjuvant immunotherapy (ipi-nivo) in patients with macroscopic stage III melanoma. Depending on tumor response after index lymph node resection (ILN), patients were offered follow up only (major pathologic response, MPR ≤10% viable melanoma); therapeutic lymph node dissection (TLND) without adjuvant therapy (partial pathologic response, pPR; 11-50% viable tumor cells), and finally, TLND +/- adjuvant radiotherapy to the nodal field, followed by adjuvant systemic therapy (pathologic non response (pNR; >50% viable tumor cells), and switch to BRAF/MEK inhibition in case of a BRAF V600 mutation. Primary endpoints were confirmation of pathologic response rate (pRR) of the ipi-nivo; to investigate whether TLND can be safely omitted in patients achieving MPR, with the hypothesis that MPR is durable and transcends the need for TLND. Results showed that MPR could be achieved 61% of patients and TLND could safely be omitted in these patients with significantly lower surgical morbidity and better QoL, with durable DFS and DMFS at 2 years. Summarizing, the PRADO trial showed that in macroscopic stage III melanoma 2 doses of neoadjuvant ipi-nivo leads to a high MPR rate and suggests TLND can be safely omitted in favor of ILN. Validation of this concept will follow in MSLT-3.
No takes yet. Share an insight, caveat, or question.
Ophuis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: